Prostate Cancer

In meeting this demand, Ablatherm-HIFU from EDAP offers efficacy rates at five years of follow up showing a 93 percent success rate by biopsy.

Ten-year efficacy data will be shared in April at the European Association of Urology meeting to be held in Paris.

Ablatherm-HIFU treatment also has significantly lower side effects such as incontinence and impotence, requires a single treatment consisting of two to three hours and allows the patient to resume a normal lifestyle in a matter of days.A 63-year old patient treated in September 2005 following a diagnosis based on his PSA screen stated: "I had a serious health problem, and I did not know about it until the PSA test results.

I'm so pleased about my treatment experience.

I went into the hospital, had the procedure at 2 pm, the catheter was removed the following day and I was then able to go home - walking out of the door.

I was back to my normal life in just days rather than weeks with other treatment options my GP presented in our discussions."Since its formal UK launch at Guy's Hospital in December 2005, the number of sites having access to Ablatherm-HIFU has increased from three to today 14 throughout the U.K.

The company's U.K.

partners,...

Read more...